Company intelligence / Profile preview

MultiVir, Inc.

Ownership: Private
Development stage: Phase 1

Overview

MultiVir has developed a pipeline of experimental tumor suppressor immune gene therapies and therapeutic vaccines. Its lead program—an oncolytic adenovirus-based gene therapy—has entered Phase I clinical trials for unspecified neoplasms. Other candidates include IL‑24 gene therapy for head and neck cancers and HSV Rb-p450 for colorectal cancer, both at earlier stages or pending trial initiation. No late-stage or commercialized products reported as of the latest available data.

Therapeutic areas: Oncology
Modalities: Gene therapy (including oncolytic viruses and immune gene therapies)Oncolytic adenoviruses, herpes simplex viruses (HSV), vaccinia virusesTherapeutic vaccines
Industry: Biotech

Drug pipeline

2 assets

Ad.p53-DC vaccine

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on MultiVir, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MultiVir, Inc..

Explore the full profile